746 related articles for article (PubMed ID: 31214202)
1. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors.
Coosemans A; Baert T; Ceusters J; Busschaert P; Landolfo C; Verschuere T; Van Rompuy AS; Vanderstichele A; Froyman W; Neven P; Van Calster B; Vergote I; Timmerman D
Int J Gynecol Cancer; 2019 Nov; 29(9):1381-1388. PubMed ID: 31685557
[TBL] [Abstract][Full Text] [Related]
4. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
5. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
[TBL] [Abstract][Full Text] [Related]
7. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
[TBL] [Abstract][Full Text] [Related]
8. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-Derived Suppressor Cells Restrain Natural Killer Cell Activity in Acute Coxsackievirus B3-Induced Myocarditis.
Müller I; Janson L; Sauter M; Pappritz K; Linthout SV; Tschöpe C; Klingel K
Viruses; 2021 May; 13(5):. PubMed ID: 34065891
[TBL] [Abstract][Full Text] [Related]
10. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
11. Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity.
Yoshida M; Taguchi A; Kawana K; Ogishima J; Adachi K; Kawata A; Nakamura H; Sato M; Fujimoto A; Inoue T; Tomio K; Mori M; Nagamatsu T; Arimoto T; Koga K; Hiraike OW; Oda K; Kiyono T; Osuga Y; Fujii T
Int J Oncol; 2018 Oct; 53(4):1580-1590. PubMed ID: 30066851
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer modulates the immunosuppressive function of CD11b
Udumula MP; Sakr S; Dar S; Alvero AB; Ali-Fehmi R; Abdulfatah E; Li J; Jiang J; Tang A; Buekers T; Morris R; Munkarah A; Giri S; Rattan R
Mol Metab; 2021 Nov; 53():101272. PubMed ID: 34144215
[TBL] [Abstract][Full Text] [Related]
13. AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.
Trillo-Tinoco J; Sierra RA; Mohamed E; Cao Y; de Mingo-Pulido Á; Gilvary DL; Anadon CM; Costich TL; Wei S; Flores ER; Ruffell B; Conejo-Garcia JR; Rodriguez PC
Cancer Res; 2019 Oct; 79(19):5034-5047. PubMed ID: 31409640
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
Zhao KL; Liu J; Jiang WN; Hao JH
Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
[No Abstract] [Full Text] [Related]
15. Immunoregulatory Effects of Myeloid-Derived Suppressor Cell Exosomes in Mouse Model of Autoimmune Alopecia Areata.
Zöller M; Zhao K; Kutlu N; Bauer N; Provaznik J; Hackert T; Schnölzer M
Front Immunol; 2018; 9():1279. PubMed ID: 29951053
[TBL] [Abstract][Full Text] [Related]
16. IRF-8 regulates expansion of myeloid-derived suppressor cells and Foxp3+ regulatory T cells and modulates Th2 immune responses to gastrointestinal nematode infection.
Valanparambil RM; Tam M; Gros PP; Auger JP; Segura M; Gros P; Jardim A; Geary TG; Ozato K; Stevenson MM
PLoS Pathog; 2017 Oct; 13(10):e1006647. PubMed ID: 28968468
[TBL] [Abstract][Full Text] [Related]
17. Imaging of Tumor-Associated Macrophages in a Transgenic Mouse Model of Orthotopic Ovarian Cancer.
He H; Chiu AC; Kanada M; Schaar BT; Krishnan V; Contag CH; Dorigo O
Mol Imaging Biol; 2017 Oct; 19(5):694-702. PubMed ID: 28233218
[TBL] [Abstract][Full Text] [Related]
18. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy.
Weber R; Groth C; Lasser S; Arkhypov I; Petrova V; Altevogt P; Utikal J; Umansky V
Cell Immunol; 2021 Jan; 359():104254. PubMed ID: 33296753
[TBL] [Abstract][Full Text] [Related]
19. Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer.
Mabuchi S; Sasano T; Komura N
Cells; 2021 Feb; 10(2):. PubMed ID: 33562495
[TBL] [Abstract][Full Text] [Related]
20. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
Horikawa N; Abiko K; Matsumura N; Hamanishi J; Baba T; Yamaguchi K; Yoshioka Y; Koshiyama M; Konishi I
Clin Cancer Res; 2017 Jan; 23(2):587-599. PubMed ID: 27401249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
